PMC6625641_01
Pathology or PET/CT images of primary and recurrent tumor tissues. (A) Pathology of postoperative samples, indicating moderately differentiated adenocarcinoma. (B) PET/CT results indicating oligo metastasis within the liver and in the right adrenal gland.
OTT-12-5389-g0001.jpg
PMC6625641_01_OTT-12-5389-g0001.jpg
F0001
T3N0M0 adenocarcinoma with moderate differentiation (Figure 1A). The patient recovered well after surgery and received no anticancer regimens. In May 2017, positron emission tomography/computed tomography (PET/CT) results revealed tumor recurrence with the right adrenal metastasis and local intrahepatic metastasis (Figure 1B).
The patient with PD-L1 strong expression. Immunohistochemical staining of PD-L1 expression. The PD-L1 expression of the patient sample was 50%. PD-L1 was stained by VENTANA PD-L1 (SP263) Assay kit following the manufacturer's instructions. Positive control and negative control were provided by the kit, indicating PD-L1-expressing and non-PD-L1-expressing tissues, respectively. The "patient sample" was paraffin section of FFPE-embedded tumor sample.
OTT-12-5389-g0002.jpg
PMC6625641_01_OTT-12-5389-g0002.jpg
F0002
IHC results indicated that the PD-L1 expression was 50% (Figure 2).
Computed tomography scan shows different lesions in lung, lymph node, left kidney, liver, and left hip during immunotherapy. (A) Lesions before immunotherapy are indicated by arrows. (B) Lesions after immunotherapy are indicated by arrows.
OTT-12-5389-g0003.jpg
PMC6625641_01_OTT-12-5389-g0003.jpg
F0003
Lesions in liver and left kidney received significant response to the treatment (Figure 3).